Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer
NL-OMON50210Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Enzalutamide with Placebo (2 arms). Primary endpoint: Metastasis-free survival. Started May 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON50210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50210.